Shots:
- Jacobio Pharma entered a global exclusive licensing agreement with AstraZeneca for JAB-23E73, granting AstraZeneca exclusive development & commercialization rights outside China, while both companies will jointly develop & commercialize in China
- As per the deal, Jacobio will receive $100M upfront, and is eligible up to $1.91B in development & commercial milestones, and tiered royalties on outside China net sales; AstraZeneca will lead all clinical development, regulatory filings & commercialization outside China
- JAB-23E73 is a pan-KRAS inhibitor targeting multiple KRAS mutation subtypes and is currently in P-I study in China & the US, with early signs of anti-tumor activity in KRAS-mutated cancers
Ref: PR Newswire | Image: Jacobio Pharma & AstraZeneca | Press Release
Related News: Alexion (AstraZeneca) and Neurimmune Expand Alliance to Develop NI009 for AL Amyloidosis
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
